INTERVENTION 1:	Intervention	0
BCD-022 (CJSC BIOCAD)	Intervention	1
BCD-022 is a product code for trastuzumab biosimilar manufactured by CJSC BIOCAD, Russia. In this arm patients will receive 6 courses of treatment with BCD-022 in combination with paclitaxel. Patients will receive BCD-022 at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations), + paclitaxel 175 mg/m2 every 3 weeks as 3 hour intravenous infusion (6 administrations).	Intervention	2
product	BAO:0003067	13-20
paclitaxel	CHEBI:45863	180-190
paclitaxel	CHEBI:45863	336-346
hour	UO:0000032	376-380
INTERVENTION 2:	Intervention	3
Herceptin ® (F. Hoffmann-La Roche Ltd., Switzerland)	Intervention	4
In this arm patients will receive 6 courses of treatment with Herceptin in combination with paclitaxel. Patients will receive Herceptin at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations), + paclitaxel 175 mg/m2 every 3 weeks as 3 hour intravenous infusion (6 administrations).	Intervention	5
paclitaxel	CHEBI:45863	92-102
paclitaxel	CHEBI:45863	250-260
hour	UO:0000032	290-294
Inclusion Criteria:	Eligibility	0
Written informed consent and ability to follow the Protocol procedures;	Eligibility	1
Age from 18 years to 75 years inclusive;	Eligibility	2
age	PATO:0000011	0-3
Female gender;	Eligibility	3
female	PATO:0000383	0-6
Histologically confirmed breast cancer (BC);	Eligibility	4
breast cancer	DOID:1612	25-38
Metastatic BC (stage IV according to TNM classification version 6);	Eligibility	5
Grade 3+ HER2 overexpression confirmed by immunohistochemical (IHC) staining or grade 2+ HER2 overexpression accompanied by HER2 gene amplification confirmed by fluorescent hybridization in situ (FISH) ;	Eligibility	6
gene	BAO:0000582	129-133
Documented results of oestrogen and progesterone receptors expression analysis;	Eligibility	7
progesterone	CHEBI:17026	36-48
Eastern Cooperative Oncology Group (ECOG) status 0, 1 or 2, not increasing within 2 weeks prior to randomization;	Eligibility	8
group	CHEBI:24433	29-34
Life expectancy - 20 weeks or more from the moment of randomization;	Eligibility	9
Presence of at least 1 tumour with a size not less than 1 cm (revealed with computed tomography (CT) slice thickness not more than 5 mm). Patients having bone metastasis as the only measurable tumour are not eligible for the trial;	Eligibility	10
size	PATO:0000117	37-41
tomography	BAO:0002525	85-95
ct	BAO:0002125	97-99
Patients of childbearing potential must implement reliable contraceptive measures during the study treatment, starting 4 weeks prior to inclusion into the trial and until 6 months after the last administration of the study drug.	Eligibility	11
drug	CHEBI:23888	223-227
Exclusion Criteria:	Eligibility	12
Previous anticancer therapy for metastatic BC, including cytotoxic chemotherapy, or previous anticancer therapy with signal transduction inhibitors (e.g. lapatinib), biological drugs (e.g. trastuzumab, bevacizumab), experimental (not approved for BC therapy) anticancer drugs. Any previous hormonal therapy is allowed;	Eligibility	13
signal transduction	GO:0007165	117-136
lapatinib	CHEBI:49603	154-163
Disease progression within 6 months after adjuvant and/or neoadjuvant anti BC therapy;	Eligibility	14
disease	DOID:4,OGMS:0000031	0-7
adjuvant	CHEBI:60809	42-50
adjuvant	CHEBI:60809	61-69
Surgery, radiation therapy, use of any experimental medications within 4 weeks (28 days) prior to randomization;	Eligibility	15
surgery	OAE:0000067	0-7
Hypersensitivity to paclitaxel and all medications containing polyoxyethylated castor oil, hypersensitivity to dexamethasone, diphenhydramine, ranitidine/cimetidine, recombinant murine proteins, contrast agents or excipients of study medications;	Eligibility	16
hypersensitivity	GO:0002524,DOID:1205	0-16
hypersensitivity	GO:0002524,DOID:1205	91-107
paclitaxel	CHEBI:45863	20-30
castor oil	CHEBI:140618	79-89
dexamethasone	CHEBI:41879	111-124
diphenhydramine	CHEBI:4636	126-141
BC metastases in central nervous system, progressing or clinically manifested (e.g. cerebral oedema, spinal cord injury), with exception of non-progressing metastases not requiring treatment with glucocorticosteroids and/or anticonvulsants within 4 weeks prior to randomization;	Eligibility	17
central nervous system	UBERON:0001017	17-39
spinal cord	UBERON:0002240	101-112
Cardiovascular system pathology (congestive heart failure (CHF) stage III-IV according to New York Heart Association (NYHA) classification, unstable angina pectoris, myocardial infarction) within 12 months prior to randomization;	Eligibility	18
cardiovascular system	UBERON:0004535	0-21
congestive heart failure	HP:0001635,DOID:6000	33-57
heart	UBERON:0000948	44-49
heart	UBERON:0000948	99-104
angina pectoris	HP:0001681	149-164
myocardial infarction	HP:0001658,DOID:5844	166-187
Uncontrolled hypertension comprising all cases of arterial hypertension when no decrease in blood pressure could be achieved despite treatment with a combination of 3 antihypertensive drugs including one diuretic and non-medicamental correction methods (low salt diet, physical exercise);	Eligibility	19
hypertension	HP:0000822,DOID:10763	13-25
hypertension	HP:0000822,DOID:10763	59-71
blood	UBERON:0000178	92-97
diuretic	CHEBI:35498	204-212
salt	CHEBI:24866	258-262
Left ventricular ejection fraction <50% according to electrocardiography;	Eligibility	20
left	HP:0012835	0-4
ejection fraction	CMO:0000180	17-34
Neutrophils 1500/mm3;	Eligibility	21
Platelets 100 000/mm3;	Eligibility	22
Hemoglobin 90 g/L;	Eligibility	23
hemoglobin	CHEBI:35143	0-10
Creatinine level  1.5 × upper limit of normal (ULN);	Eligibility	24
creatinine	CHEBI:16737	0-10
Bilirubin level  1.5 × ULN;	Eligibility	25
Asparagine transferase (AST) and alanine transferase (ALT) levels  2.5 × ULN (5 × ULN for patients with liver metastases);	Eligibility	26
asparagine	CHEBI:22653	0-10
transferase	BAO:0000292	11-22
transferase	BAO:0000292	41-52
alanine	CHEBI:16449	33-40
liver	UBERON:0002107	104-109
Alkaline phosphatase level  5 × ULN;	Eligibility	27
phosphatase	GO:0016791,BAO:0000295	9-20
Pregnancy or lactation;	Eligibility	28
lactation	GO:0007595	13-22
Any other concomitant cancer including contralateral breast cancer revealed within 5 years prior to screening, except curatively treated intraductal carcinoma in situ, curatively treated cervical carcinoma in situ or curatively treated basal cell or squamous cell carcinoma;	Eligibility	29
cancer	DOID:162	22-28
cancer	DOID:162	60-66
breast cancer	DOID:1612	53-66
carcinoma	HP:0030731,DOID:305	149-158
carcinoma	HP:0030731,DOID:305	196-205
carcinoma	HP:0030731,DOID:305	264-273
squamous cell carcinoma	HP:0002860,DOID:1749	250-273
Conditions limiting patient's adherence to protocol requirements (dementia, neurologic or psychiatric disorders, drug addiction, alcoholism and others);	Eligibility	30
patient	HADO:0000008,OAE:0001817	20-27
dementia	HP:0000726,DOID:1307	66-74
drug addiction	HP:0033511	113-127
alcoholism	HP:0030955,DOID:0050741	129-139
Stage II-IV neuropathy according to Common Terminology Criteria for Adverse Events (CTCAE) v.4.0;	Eligibility	31
neuropathy	DOID:870	12-22
Concomitant participation in other clinical trials, previous participation in other clinical trials within 30 days before entering into the trial, previous participation in the same trial;	Eligibility	32
Acute or active chronic infections;	Eligibility	33
acute	HP:0011009,PATO:0000389	0-5
active	PATO:0002354	9-15
chronic	HP:0011010	16-23
Hepatitis C virus, hepatitis B virus, HIV or syphilis infections;	Eligibility	34
hepatitis c	DOID:1883	0-11
virus	BAO:0000232	12-17
virus	BAO:0000232	31-36
hepatitis b	DOID:2043	19-30
syphilis	DOID:4166	45-53
Obstacles in intravenous administration of study drugs	Eligibility	35
Outcome Measurement:	Results	0
Overall Response Rate	Results	1
rate	BAO:0080019	17-21
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.	Results	2
target	BAO:0003064	76-82
target	BAO:0003064	157-163
target	BAO:0003064	249-255
diameter	PATO:0001334	237-245
The response was assessed at the screening, after 3 therapy cycles and after 6 therapy cycles. If CT after 3 or 6 therapy cycles revealed the complete or partial response, a confirmatory CT scan was performed 4 weeks later. The best response during the study was assessed.	Results	3
ct	BAO:0002125	98-100
ct	BAO:0002125	187-189
Time frame: Day 127	Results	4
time	PATO:0000165	0-4
day	UO:0000033	12-15
Results 1:	Results	5
Arm/Group Title: BCD-022 (CJSC BIOCAD)	Results	6
Arm/Group Description: BCD-022 is a product code for trastuzumab biosimilar manufactured by CJSC BIOCAD, Russia. In this arm patients will receive 6 courses of treatment with BCD-022 in combination with paclitaxel. Patients will receive BCD-022 at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations), + paclitaxel 175 mg/m2 every 3 weeks as 3 hour intravenous infusion (6 administrations).	Results	7
product	BAO:0003067	36-43
paclitaxel	CHEBI:45863	203-213
paclitaxel	CHEBI:45863	359-369
hour	UO:0000032	399-403
Overall Number of Participants Analyzed: 113	Results	8
Measure Type: Count of Participants	Results	9
Unit of Measure: Participants  56  49.6%	Results	10
Results 2:	Results	11
Arm/Group Title: Herceptin    (F. Hoffmann-La Roche Ltd., Switzerland)	Results	12
Arm/Group Description: In this arm patients will receive 6 courses of treatment with Herceptin in combination with paclitaxel. Patients will receive Herceptin at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations), + paclitaxel 175 mg/m2 every 3 weeks as 3 hour intravenous infusion (6 administrations).	Results	13
paclitaxel	CHEBI:45863	115-125
paclitaxel	CHEBI:45863	273-283
hour	UO:0000032	313-317
Overall Number of Participants Analyzed: 110	Results	14
Measure Type: Count of Participants	Results	15
Unit of Measure: Participants  48  43.6%	Results	16
Adverse Events 1:	Adverse Events	0
Total: 8/113 (7.08%)	Adverse Events	1
Febrile neutropenia [1]0/113 (0.00%)	Adverse Events	2
neutropenia	HP:0001875,DOID:1227	8-19
Anemia with trombocytopenia  0/113 (0.00%)	Adverse Events	3
anemia	HP:0001903,DOID:2355	0-6
Neutropenia  1/113 (0.88%)	Adverse Events	4
neutropenia	HP:0001875,DOID:1227	0-11
Paroxism of atrial fibrillation  0/113 (0.00%)	Adverse Events	5
atrial fibrillation	HP:0005110,DOID:0060224	12-31
Ventricular extrasystolone RYAN-1  0/113 (0.00%)	Adverse Events	6
Gastrointestinal hemorrhage  1/113 (0.88%)	Adverse Events	7
gastrointestinal hemorrhage	HP:0002239	0-27
Death for unknown reason  1/113 (0.88%)	Adverse Events	8
death	OAE:0000632	0-5
Diarrhea with vomiting and weakness  0/113 (0.00%)	Adverse Events	9
diarrhea	HP:0002014,DOID:13250	0-8
vomiting	HP:0002013	14-22
Adverse Events 2:	Adverse Events	10
Total: 13/110 (11.82%)	Adverse Events	11
Febrile neutropenia [1]1/110 (0.91%)	Adverse Events	12
neutropenia	HP:0001875,DOID:1227	8-19
Anemia with trombocytopenia  1/110 (0.91%)	Adverse Events	13
anemia	HP:0001903,DOID:2355	0-6
Neutropenia  1/110 (0.91%)	Adverse Events	14
neutropenia	HP:0001875,DOID:1227	0-11
Paroxism of atrial fibrillation  2/110 (1.82%)	Adverse Events	15
atrial fibrillation	HP:0005110,DOID:0060224	12-31
Ventricular extrasystolone RYAN-1  1/110 (0.91%)	Adverse Events	16
Gastrointestinal hemorrhage  0/110 (0.00%)	Adverse Events	17
gastrointestinal hemorrhage	HP:0002239	0-27
Death for unknown reason  1/110 (0.91%)	Adverse Events	18
death	OAE:0000632	0-5
Diarrhea with vomiting and weakness  1/110 (0.91%)	Adverse Events	19
diarrhea	HP:0002014,DOID:13250	0-8
vomiting	HP:0002013	14-22
